Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Given their good antitumor effects, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. EGFR fusion mutations and EGFR amplification are very rare in non-small...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Zhulin Wang, Chunyao Huang, Wenbo Fan, Shaowu Sun, Kaiyuan Li, Xu Liu, Jiangtao Pu, Guoqing Zhang, Xiangnan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Subjects:	EGFR fusion EGFR amplification rare mutations lung adenocarcinoma targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1347282/full